PUMA BIOTECHNOLOGY, INC. (PBYI)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, PUMA BIOTECHNOLOGY, INC. reported revenue of $228.37M, down 0.9% from the prior year. The company was profitable, with a net margin of 13.6%. It held $216.30M in total assets against $85.96M in total liabilities.
Key ratios (FY2025)
16.3%
Operating margin
13.6%
Net margin
23.9%
Return on equity
-0.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $228.37M | $230.47M | $235.64M | $228.03M | $253.16M | $225.11M | $272.26M | $250.99M | $27.68M | — |
| Cost of Revenue | $58.16M | $64.40M | $62.68M | $55.09M | $63.70M | $39.37M | $36.81M | $34.62M | $5.57M | — |
| Operating Income | $37.30M | $30.97M | $32.64M | $23.72M | $1.29M | -$30.40M | -$39.05M | -$94.66M | -$292.39M | -$276.60M |
| Net Income | $31.11M | $30.28M | $21.59M | $2.0K | -$29.13M | -$59.99M | -$75.59M | -$113.58M | -$291.95M | -$276.01M |
| EPS (Diluted) | $0.62 | $0.62 | $0.46 | $0.00 | $-0.72 | $-1.52 | $-75595.00 | — | — | — |
| Total Assets | $216.30M | $213.33M | $230.53M | $222.06M | $226.59M | $244.22M | $234.91M | $259.12M | $165.53M | $252.79M |
| Total Liabilities | $85.96M | $121.21M | $177.09M | $200.45M | $229.03M | $250.17M | $217.44M | $224.82M | $112.22M | $42.97M |
| Shareholders' Equity | $130.34M | $92.12M | $53.44M | $21.61M | -$2.45M | -$5.95M | $17.46M | $34.31M | $53.30M | $209.82M |
| Cash & Equivalents | $29.64M | $69.22M | $84.58M | $76.20M | $63.13M | $85.29M | $60.04M | $108.42M | $81.70M | $194.49M |
| Operating Cash Flow | $41.80M | $38.92M | $27.01M | -$15.83M | $20.65M | $773.0K | $22.38M | -$24.11M | -$172.47M | -$141.69M |
| Capital Expenditures | $71.0K | $56.0K | $140.0K | $0 | $0 | $46.0K | $306.0K | $439.0K | $431.0K | $4.29M |
| Shares Outstanding | 50.41M | 49.11M | 47.65M | 46.35M | 41.18M | 40.09M | 39.20M | 38.33M | 37.59M | 36.83M |